AzTrials
AzTrials

Type 1 Diabetes Mellitus With HypoglycemiaSUPPORTNCT04233138

SUPPORT Online Training Platform for Type 1 Diabetes Self-management Education and Support (SUPPORT)

A study testing SUPPORT online platform for people with type 1 diabetes in people with Type 1 Diabetes Mellitus With Hypoglycemia, run by McGill University at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There are evidences that some healthcare teams are not proposing new therapeutic and technology options that have the potential to reduce hypoglycemia for people with type 1 diabetes. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
SUPPORT online platform for people with type 1 diabetes
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
285 participants
Where
1 siteCanada
Study dates
5 Feb 2020to 19 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ≥ 18 years old
  • Completed phase 2 of the BETTER registry
  • Self-reported diagnosis of type 1 diabetes for ≥ 1 year
  • Daily use of ≥ 4 injections of insulin or CSII
  • Have access to Internet
  • Use of an active email address
  • Comprehension of English or French

Who cannot join

  • Ongoing pregnancy
  • Other illnesses limiting diabetes care or access to the platform (e.g. dementia and blindness)

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Institut de recherches cliniques de Montréal

    Montreal, Quebec, H2W1R7

Other trials in Canada

About this study

Official title: Optimizing Therapies and Technologies to Reduce Hypoglycemia in Type 1 Diabetes Through the SUPPORT Online Platform for Self-management Education and Support

There are evidences that some healthcare teams are not proposing new therapeutic and technology options that have the potential to reduce hypoglycemia for people with type 1 diabetes. In practice, people living with type 1 diabetes report receiving education related to insulin pumps usage mainly on key functions (how the device works) at initiation and not enough about proactive adjustments (how to optimally use the device) especially on the long-term. In brief, short-term education is technical and product-specific, rather than being based on patients' needs.There is a need to test the efficacy of different programs that may be more suited to patients' needs and desires while offering the opportunity to reduce costs (e.g. web based). Since there is a lack of expertise related to optimal use of new technologies and therapies for people living with type 1 diabetes, we propose to design and test a web-based training (e.g. courses including videos and quizzes) and support (e.g. discussion forum) platform. This will be tested through a registry-based trial.

The overall purpose of this study is to evaluate, among a group of adults living with type 1 diabetes, the SUPPORT online education platform in terms of users' satisfaction, engagement and efficacy to change the fear and the frequency of hypoglycemia.

Read the detailed description

Design and development of the SUPPORT platform:

The SUPPORT platform was designed based on the Behavior change wheel framework. The research team identified the main barriers in achieving adequate blood glucose management and in the use of an online training platform; then, features (downloadable PDFs, videos, quizzes, etc.) were designed to overcome these barriers. These training modules were developed by a team including two dietitians/certified diabetes educator, a nurse, a psychologist and endocrinologist (all specialized in type 1 diabetes). The content was then reviewed by the committee of patient-partners and clinicians working in type 1 diabetes (one endocrinologist, two residents in endocrinology, two dietitians (1 being a certified diabetes educator) and two nurses (1 being a certified diabetes educator).

Recruitment and intervention:

Recruitment of people with type 1 diabetes will be done via an email sent to the participants who completed phase 2 of the BETTER registry, are 18 years old or older, and agreed to be contacted for other studies. All participants accepting to participate will receive the full intervention for 6 months (access to the platform with bi-weekly newsletters). During the following 6 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase). Questionnaires will be given at baseline, 6-month, and 12-month of the intervention to assess fear of hypoglycemia, diabetes knowledge, overall satisfaction of the platform. Participant will also receive 1 question every 6 weeks regarding the frequency of hypoglycemia during the last 3 days. The observational control group will not have access to the platform. We will extract data from the baseline, 6 months and annual registry completion.

Analysis:

Initial analysis will be descriptive and baseline data will be summarized separately for both groups. Baseline continuous data will be reported as means with standard deviations (median and interquartile range if data are skewed). Categorical data will be reported as proportions. Our primary outcome is the difference in mean self-reported hypoglycemia and fear of hypoglycemia score between the 2 groups after 6 months of intervention. The primary outcome will be calculated and compared between the two groups using differences with 95% CI using paired t-test and McNemar test. Analysis will be by intention to treat.

Sample size and pairing:

Every participant in the intervention group will be randomly paired by gender and date of completion of the phase 2 BETTER questionnaire (+/- 1 month) with a participant who answered the second phase of the BETTER registry but who did not respond to the invitation e-mail for the SUPPORT study. We have calculated the number of pairs to be able to detect a 25% reduction in adults given the small but present difference in self-reported hypoglycemia in both age groups. We estimate a 25% reduction in hypoglycemic episodes for a between-group difference of 0.95. Assuming a common standard deviation of 4.5, for a 2-sided alpha=0.05 and 80% power to detect such a difference with sample size calculation for comparing paired differences, we will require 179 pairs of participants in total. Allowing for a up to 35% loss to follow-up, we will require 275 pairs of participants.

Importance of this study:

Once validated, the SUPPORT online training platform for individuals with type 1 diabetes can be a low-cost and easily accessible training to complement regular care and increase knowledge of diabetes-related therapies and technologies.

Being tested
SUPPORT online platform for people with type 1 diabetes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SUPPORT online platform for people with type 1 diabetesOther

    All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).

    The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform.

Study groups in NCT04233138
Study groupRoleWhat they receive
InterventionExperimentalThe intervention group will have immediate access to the SUPPORT platform.
Receives: Other: SUPPORT online platform for people with type 1 diabetes

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Users' satisfaction of the SUPPORT platform

    Online questionnaire- General satisfaction of the SUPPORT platform-8 items

    Measured: after 6 months

Secondary outcomes (4)
  1. Users' engagement on the SUPPORT platform

    Extracted from Google Analytics: Number of page viewed, time spent on the platform, number of downloaded PDFs, number of forum posts

    Measured: baseline to 6 months

  2. Change in the frequency and the fear of hypoglycemia

    Self-reported (compared to baseline)

    Measured: 6-month, and 12-month

  3. Change in the glycated hemoglobin

    Self-reported (compared to baseline)

    Measured: at 6 months and 12 months

  4. Knowledge about diabetes self-management

    Online questionnaire based on content seen on the SUPPORT platform- 7 items

    Measured: at baseline, 6 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jan 2020
  2. Study start5 Feb 2020
  3. Primary completion19 Mar 2023
  4. Study completion19 Sep 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Model description
Participants enrolling in the study have access to the online platform for 12 months (6 months with reminders, 6 months no reminders).
Masking
None (open label)
Enrolment
285 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04233138
Sponsor's protocol ID
SUPPORT
Acronym
SUPPORT
Status last verified
Apr 2022
First submitted
15 Jan 2020
Last updated
25 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Xie LF, Housni A, Roy-Fleming A, Bandini A, Delormier T, Costa DD, Brazeau AS. Evaluation of Support, a self-guided online type 1 diabetes self-management education and support web application-a mixed methods study. Digit Health. 2023 Sep 28;9:20552076231204435. doi: 10.1177/20552076231204435. eCollection 2023 Jan-Dec.

    PubMed 37780064

Questions about this trial

What is this clinical trial studying?

A study testing SUPPORT online platform for people with type 1 diabetes in people with Type 1 Diabetes Mellitus With Hypoglycemia, run by McGill University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Users' satisfaction of the SUPPORT platform (time frame: after 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04233138, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in